AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
出版年份 2022 全文链接
标题
AGA Clinical Practice Guideline on Pharmacological Interventions for Adults With Obesity
作者
关键词
-
出版物
GASTROENTEROLOGY
Volume 163, Issue 5, Pages 1198-1225
出版商
Elsevier BV
发表日期
2022-10-20
DOI
10.1053/j.gastro.2022.08.045
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes
- (2022) Domenica M. Rubino et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
- (2022) Takashi Kadowaki et al. Lancet Diabetes & Endocrinology
- Tirzepatide Once Weekly for the Treatment of Obesity
- (2022) Ania M. Jastreboff et al. NEW ENGLAND JOURNAL OF MEDICINE
- Changes in the Incidence of Childhood Obesity
- (2022) Solveig A. Cunningham et al. PEDIATRICS
- Pharmacogenomics of Medication‐Induced Weight Gain and Antiobesity Medications
- (2021) Sneha Singh et al. Obesity
- Use of Weight Loss Medications in Patients after Bariatric Surgery
- (2021) Ilana P. Redmond et al. Current Obesity Reports
- Prescribing trends and clinical characteristics of patients starting antiobesity drugs in the U.S.
- (2021) Karine Suissa et al. DIABETES OBESITY & METABOLISM
- Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity
- (2021) Thomas A. Wadden et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial
- (2021) Melanie Davies et al. LANCET
- Once-Weekly Semaglutide in Adults with Overweight or Obesity
- (2021) John P.H. Wilding et al. NEW ENGLAND JOURNAL OF MEDICINE
- AGA Clinical Practice Guidelines on Intragastric Balloons in the Management of Obesity
- (2021) Thiruvengadam Muniraj et al. GASTROENTEROLOGY
- AGA Technical Review on Intragastric Balloons in the Management of Obesity
- (2021) Raj Shah et al. GASTROENTEROLOGY
- Glucose-Lowering Drugs to Reduce Cardiovascular Risk in Type 2 Diabetes
- (2021) Rita R. Kalyani NEW ENGLAND JOURNAL OF MEDICINE
- Healthy Weight Loss Maintenance with Exercise, Liraglutide, or Both Combined
- (2021) Julie R. Lundgren et al. NEW ENGLAND JOURNAL OF MEDICINE
- Selection of Antiobesity Medications Based on Phenotypes Enhances Weight Loss: A Pragmatic Trial in an Obesity Clinic
- (2021) Andres Acosta et al. Obesity
- Semaglutide for obesity: four STEPs forward, but more to come
- (2021) Donna H Ryan Lancet Diabetes & Endocrinology
- Three- and six-month efficacy and safety of phentermine in a Mexican obese population
- (2021) Maribel Márquez-Cruz et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes
- (2021) Juan P. Frías et al. NEW ENGLAND JOURNAL OF MEDICINE
- Cardiovascular Safety and Superiority of Anti-Obesity Medications
- (2021) Muath Alobaida et al. Diabetes Metabolic Syndrome and Obesity-Targets and Therapy
- Randomised clinical trial: semaglutide versus placebo reduced liver steatosis but not liver stiffness in subjects with non‐alcoholic fatty liver disease assessed by magnetic resonance imaging
- (2021) Anne Flint et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Trends in Obesity Prevalence Among Adults Aged 18 Through 25 Years, 1976-2018
- (2021) Alejandra Ellison-Barnes et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials
- (2021) Qingyang Shi et al. LANCET
- Efficacy and Safety of Liraglutide 3.0 mg in Individuals With Overweight or Obesity and Type 2 Diabetes Treated With Basal Insulin: The SCALE Insulin Randomized Controlled Trial
- (2020) W. Timothy Garvey et al. DIABETES CARE
- Liraglutide 3.0 mg and Intensive Behavioral Therapy (IBT) for Obesity in Primary Care: The SCALE IBT Randomized Controlled Trial
- (2020) Thomas A. Wadden et al. Obesity
- SELECT (Semaglutide effects on cardiovascular outcomes in people with overweight or obesity) rationale and design
- (2020) Donna H. Ryan et al. AMERICAN HEART JOURNAL
- Obesity in adults: a clinical practice guideline
- (2020) Sean Wharton et al. CANADIAN MEDICAL ASSOCIATION JOURNAL
- Effect of setmelanotide, a melanocortin‐4 receptor agonist, on obesity in Bardet‐Biedl syndrome
- (2020) Robert Haws et al. DIABETES OBESITY & METABOLISM
- Addressing Disparities in the Management of Obesity in Primary Care Settings
- (2020) Thomas A. Wadden et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pharmacotherapy for Obesity—Trends Using a Population Level National Database
- (2020) Abbinaya Elangovan et al. OBESITY SURGERY
- Liraglutide after diet-induced weight loss for pain and weight control in knee osteoarthritis: a randomized controlled trial
- (2020) Henrik Gudbergsen et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Efficacy of Liraglutide to Prevent Weight Regain After Retrieval of an Adjustable Intra-gastric Balloon—a Case-Matched Study
- (2020) Dilhana Badurdeen et al. OBESITY SURGERY
- Efficacy and safety of setmelanotide, an MC4R agonist, in individuals with severe obesity due to LEPR or POMC deficiency: single-arm, open-label, multicentre, phase 3 trials
- (2020) Karine Clément et al. Lancet Diabetes & Endocrinology
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis
- (2020) Philip N. Newsome et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and Effectiveness of Longer‐Term Phentermine Use: Clinical Outcomes from an Electronic Health Record Cohort
- (2019) Kristina H. Lewis et al. Obesity
- The Discovery and Development of Liraglutide and Semaglutide
- (2019) Lotte Bjerre Knudsen et al. Frontiers in Endocrinology
- Intensity and duration of lifestyle interventions for long-term weight loss and association with mortality: a meta-analysis of randomised trials
- (2019) Navneet Singh et al. BMJ Open
- Glucagon-like peptide 1 (GLP-1)
- (2019) T.D. Müller et al. Molecular Metabolism
- Antiobesity Medication Use in 2.2 Million Adults Across Eight Large Health Care Organizations: 2009‐2015
- (2019) David R. Saxon et al. Obesity
- Obesity Pharmacotherapy
- (2018) Katherine H. Saunders et al. MEDICAL CLINICS OF NORTH AMERICA
- Efficacy and safety of semaglutide compared with liraglutide and placebo for weight loss in patients with obesity: a randomised, double-blind, placebo and active controlled, dose-ranging, phase 2 trial
- (2018) Patrick M O'Neil et al. LANCET
- Phentermine
- (2018) Soobin Lim et al. ANNALS OF PLASTIC SURGERY
- A Randomized, Double-Blind, Placebo-Controlled Study of Gelesis100: A Novel Nonsystemic Oral Hydrogel for Weight Loss
- (2018) Frank L. Greenway et al. Obesity
- Intensive Behavioral Therapy for Obesity Combined with Liraglutide 3.0 mg: A Randomized Controlled Trial
- (2018) Thomas A. Wadden et al. Obesity
- 3 years of liraglutide versus placebo for type 2 diabetes risk reduction and weight management in individuals with prediabetes: a randomised, double-blind trial
- (2017) Carel W le Roux et al. LANCET
- Bupropion and naltrexone for smoking cessation: A double-blind randomized placebo-controlled clinical trial
- (2016) ME Mooney et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY COMPREHENSIVE CLINICAL PRACTICE GUIDELINES FOR MEDICAL CARE OF PATIENTS WITH OBESITY
- (2016) W. Timothy Garvey et al. Endocrine Practice
- Effect of Naltrexone-Bupropion on Major Adverse Cardiovascular Events in Overweight and Obese Patients With Cardiovascular Risk Factors
- (2016) Steven E. Nissen et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Association of Pharmacological Treatments for Obesity With Weight Loss and Adverse Events
- (2016) Rohan Khera et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes
- (2016) Steven P. Marso et al. NEW ENGLAND JOURNAL OF MEDICINE
- Low adoption of weight loss medications: A comparison of prescribing patterns of antiobesity pharmacotherapies and SGLT2s
- (2016) Catherine E. Thomas et al. Obesity
- Six-month efficacy and safety of amfepramone in obese Mexican patients: a double-blinded, randomized, controlled trial
- (2015) Herman Soto-Molina et al. INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes
- (2015) Melanie J. Davies et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Pharmacological Management of Obesity: An Endocrine Society Clinical Practice Guideline
- (2015) Caroline M. Apovian et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management
- (2015) Xavier Pi-Sunyer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Is 5% weight loss a satisfactory criterion to define clinically significant weight loss?
- (2015) Donald A. Williamson et al. Obesity
- Weight-Loss Therapy in Type 2 Diabetes: Effects of Phentermine and Topiramate Extended Release
- (2014) W. Timothy Garvey et al. DIABETES CARE
- How Physician Obesity Medicine Specialists Treated Obesity before 2012 New Drug Approvals
- (2014) Stacy L. Schmidt et al. OBESITY SURGERY
- Long term maintenance of weight loss with non-surgical interventions in obese adults: systematic review and meta-analyses of randomised controlled trials
- (2014) S. U. Dombrowski et al. BMJ-British Medical Journal
- 2013 AHA/ACC/TOS Guideline for the Management of Overweight and Obesity in Adults
- (2013) Michael D. Jensen et al. CIRCULATION
- The AGA Institute Process for Developing Clinical Practice Guidelines Part One: Grading the Evidence
- (2013) Shahnaz Sultan et al. Clinical Gastroenterology and Hepatology
- Effects of Naltrexone Sustained- Release/Bupropion Sustained-Release Combination Therapy on Body Weight and Glycemic Parameters in Overweight and Obese Patients With Type 2 Diabetes
- (2013) P. Hollander et al. DIABETES CARE
- A comparative study of five centrally acting drugs on the pharmacological treatment of obesity
- (2013) H Suplicy et al. INTERNATIONAL JOURNAL OF OBESITY
- Weight maintenance and additional weight loss with liraglutide after low-calorie-diet-induced weight loss: The SCALE Maintenance randomized study
- (2013) T A Wadden et al. INTERNATIONAL JOURNAL OF OBESITY
- Cardiovascular Effects of Intensive Lifestyle Intervention in Type 2 Diabetes
- (2013) NEW ENGLAND JOURNAL OF MEDICINE
- Evaluation of phentermine and topiramate versus phentermine/topiramate extended-release in obese adults
- (2013) Louis J. Aronne et al. Obesity
- A randomized, phase 3 trial of naltrexone SR/bupropion SR on weight and obesity-related risk factors (COR-II)
- (2013) Caroline M. Apovian et al. Obesity
- Use of topiramate in pregnancy and risk of oral clefts
- (2012) Andrea V. Margulis et al. AMERICAN JOURNAL OF OBSTETRICS AND GYNECOLOGY
- Zonisamide for Weight Reduction in Obese Adults
- (2012) Kishore M. Gadde et al. ARCHIVES OF INTERNAL MEDICINE
- Two-year sustained weight loss and metabolic benefits with controlled-release phentermine/topiramate in obese and overweight adults (SEQUEL): a randomized, placebo-controlled, phase 3 extension study
- (2011) W Timothy Garvey et al. AMERICAN JOURNAL OF CLINICAL NUTRITION
- Benefits of Modest Weight Loss in Improving Cardiovascular Risk Factors in Overweight and Obese Individuals With Type 2 Diabetes
- (2011) R. R. Wing et al. DIABETES CARE
- Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
- (2011) A Astrup et al. INTERNATIONAL JOURNAL OF OBESITY
- GRADE guidelines: 3. Rating the quality of evidence
- (2011) Howard Balshem et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- GRADE guidelines 6. Rating the quality of evidence—imprecision
- (2011) Gordon H. Guyatt et al. JOURNAL OF CLINICAL EPIDEMIOLOGY
- Effects of low-dose, controlled-release, phentermine plus topiramate combination on weight and associated comorbidities in overweight and obese adults (CONQUER): a randomised, placebo-controlled, phase 3 trial
- (2011) Kishore M Gadde et al. LANCET
- Blood Pressure and Heart Rate Effects, Weight Loss and Maintenance During Long-Term Phentermine Pharmacotherapy for Obesity
- (2011) Ed J. Hendricks et al. Obesity
- Controlled-Release Phentermine/Topiramate in Severely Obese Adults: A Randomized Controlled Trial (EQUIP)
- (2011) David B. Allison et al. Obesity
- Serotonin receptors and heart valve disease—It was meant 2B
- (2011) Joshua D. Hutcheson et al. PHARMACOLOGY & THERAPEUTICS
- Randomized controlled trial to investigate the effects of a newly developed formulation of phentermine diffuse-controlled release for obesity
- (2010) J. G. Kang et al. DIABETES OBESITY & METABOLISM
- Comparison of orlistat treatment and placebo in obese type 2 diabetic patients
- (2010) Giuseppe Derosa et al. EXPERT OPINION ON PHARMACOTHERAPY
- Effect of naltrexone plus bupropion on weight loss in overweight and obese adults (COR-I): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial
- (2010) Frank L Greenway et al. LANCET
- Weight Loss With Naltrexone SR/Bupropion SR Combination Therapy as an Adjunct to Behavior Modification: The COR-BMOD Trial
- (2010) Thomas A. Wadden et al. Obesity
- Nephrolithiasis in topiramate users
- (2010) Naim M. Maalouf et al. UROLOGICAL RESEARCH
- An open-label study of naltrexone and bupropion combination therapy for smoking cessation in overweight and obese subjects
- (2009) Charles S. Wilcox et al. ADDICTIVE BEHAVIORS
- Combination pharmaceutical therapies for obesity
- (2009) Kishore M Gadde et al. EXPERT OPINION ON PHARMACOTHERAPY
- A randomized double-blind placebo-controlled study of the long-term efficacy and safety of diethylpropion in the treatment of obese subjects
- (2009) C Cercato et al. INTERNATIONAL JOURNAL OF OBESITY
- Effects of liraglutide in the treatment of obesity: a randomised, double-blind, placebo-controlled study
- (2009) Arne Astrup et al. LANCET
- Rational Design of a Combination Medication for the Treatment of Obesity
- (2008) Frank L. Greenway et al. Obesity
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More